Search | Clinical Trials Finder

Conditions: Breast Cancer
Interventions: Inavolisib, Fulvestrant, Alpelisib, Bupropion, Omeprazole, Midazolam; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 39
States / cities: Greenbrae, California • Los Alamitos, California • Los Angeles, California + 32 more

Conditions: Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
Interventions: BMS-986165, Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Prostate Cancer
Interventions: Premarin; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Ipatasertib, Placebo, Palbociclib, Fulvestrant; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 5
States / cities: Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 1 more

Conditions: Sciatic Nerve Injury
Interventions: Autologous human Schwann cells; Biological
Lead sponsor: W. Dalton Dietrich; Other
Eligibility: 18 Years to 65 Years · Female only
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pelvic Pain
Interventions: Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 35 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions: anastrozole, gefitinib, fulvestrant, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Polycystic Ovarian Syndrome, Obesity, Hepatic Steatosis
Interventions: oral glucose tolerance test, MRI of liver; Diagnostic Test
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Years to 21 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Breast Cancer
Interventions: fulvestrant, sorafenib tosylate; Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Premature Ovarian Insufficiency
Interventions: Progesterone, Estrogen Patch; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 11 Years to 19 Years · Female only
Enrollment: 185 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cancer, Solid Tumors
Interventions: Vevorisertib, Fulvestrant, Paclitaxel; Drug
Lead sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA); Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 6
States / cities: Las Vegas, Nevada • Oklahoma City, Oklahoma • Charleston, South Carolina + 3 more

Conditions: Smoking, Smoking Cessation, Smoking Reduction
Interventions: Progesterone 200 MG Oral Capsule; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Breast Neoplasms, Neoplasm Metastasis
Interventions: LY4064809, Placebo, Ribociclib, Palbociclib, Abemaciclib, Anastrozole, Letrozole, Exemestane, Fulvestrant; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 129
States / cities: Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 110 more

Conditions: Ductal Breast Carcinoma In Situ, Postmenopausal
Interventions: Conjugated Estrogens/Bazedoxifene, Laboratory Biomarker Analysis, Pharmacological Study, Placebo, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 79 Years · Female only
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 10
States / cities: Aurora, Colorado • Chicago, Illinois • Geneva, Illinois + 7 more

Conditions: Exercise-related Amenorrhea
Interventions: Transdermal 17Beta-estradiol, progesterone, Ethinyl Estradiol + Desogestrel, Sham Comparator; Drug · Dietary Supplement
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 14 Years to 21 Years · Female only
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neoplasm Malignant, Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
Interventions: XL102, Fulvestrant, Abiraterone, Prednisone; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Atlanta, Georgia • Boston, Massachusetts • Dallas, Texas + 2 more

Conditions: Healthy
Interventions: PF-06650833, Ethinyl estradiol (EE) and levonogestrel (LN); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Breast Cancer
Interventions: TTI-101, Palbociclib, Aromatase inhibitor (AI), fulvestrant, ribociclib; Drug
Lead sponsor: Tvardi Therapeutics, Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Fort Lauderdale, Florida • St Louis, Missouri • Nashville, Tennessee + 2 more

Conditions: HIV, Prophylaxis, Transgender
Interventions: Truvada alone, Truvada plus Leuprolide 11.25mg intramuscular injection, Truvada plus Estradiol 1 mg, Truvada plus Estradiol 6 mg, Estradiol 6 mg alone; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Uterine Hemorrhage, Menorrhagia
Interventions: Provera, Combination Birth Control pills; Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Interventions: Ribociclib, Fulvestrant, Anastrozole, Letrozole, Exemestane; Drug
Lead sponsor: Oana Danciu; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 21
States / cities: Birmingham, Alabama • Phoenix, Arizona • Washington D.C., District of Columbia + 18 more

Conditions: Primary Dysmenorrhea
Interventions: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027), Ethinyl estradiol, Levonorgestrel (Miranova), Placebo Match to SH T00658ID, Placebo Match to SH D593B; Drug
Lead sponsor: Bayer; Industry
Eligibility: 14 Years to 50 Years · Female only
Enrollment: 507 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 10
States / cities: Tucson, Arizona • San Diego, California • Hialeah, Florida + 7 more

Conditions: Healthy Female Volunteers
Interventions: PF-06700841, Ethinyl estradiol (EE) and levonorgestrel (LN); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 2
States / cities: Coral Gables, Florida • Miami, Florida

Search by objective public record fields.

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer

A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer

Emergent Expanded Access for ahSC Augmentation of Nerve Autografts After Severe Peripheral Nerve Injury.

Phenotyping of Idiopathic Pelvic Pain With Real-time Uterine Imaging and Relugolix-Combination Therapy Treatment

Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer

Post-Prandial Liver Glucose Metabolism in PCOS

Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy

Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency

Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)

Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

The PROMISE Study: Duavee in Women With DCIS

Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

A Study To Estimate The Effect of PF-06650833 On The Pharmacokinetics (PK) of Oral Contraceptive (OC)

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW

Treatment of Non-Gestational Acute Uterine Bleeding: A Randomized Trial

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

Effect on Primary Dysmenorrhea

Effect Of Multiple Dose PF-06700841 On The Pharmacokinetics Of Single Dose Oral Contraceptive Steroids